Gastroenterology
Volume 138, Issue 5 , Pages 1854-1862.e1 , May 2010

Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency

  • Ajay Goel

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Baylor University, Medical Center, Dallas, Texas
    • Corresponding Author InformationAjay Goel, PhD, Gastointestinal Research Lab, Baylor University Medical Center, 3500 Gaston Avenue, Suite H-250, Dallas, Texas 75246. fax: (214) 818-9292
    • ,
  • Rosa M. Xicola

      Affiliations

    • Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, Illinois
    • ,
  • Thuy–Phuong Nguyen

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Baylor University, Medical Center, Dallas, Texas
    • ,
  • Brian J. Doyle

      Affiliations

    • Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, Illinois
    • ,
  • Vanessa R. Sohn

      Affiliations

    • Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, Illinois
    • ,
  • Prathap Bandipalliam

      Affiliations

    • Division of Population Sciences, Dana-Farber Cancer Institute and Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Laura S. Rozek

      Affiliations

    • School of Public Health, University of Michigan, Ann Arbor, Michigan
    • ,
  • Josep Reyes

      Affiliations

    • Gastroenterology Department, Hospital Comarcal Inca, Mallorca, Spain
    • ,
  • Carmen Cordero

      Affiliations

    • Gastroenterology Department, Hospital Virgen del Rocio, Sevilla, Spain
    • ,
  • Francesc Balaguer

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Baylor University, Medical Center, Dallas, Texas
    • ,
  • Antoni Castells

      Affiliations

    • Gastroenterology Department, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Catalonia, Spain
    • ,
  • Rodrigo Jover

      Affiliations

    • Gastroenterology Unit, Hospital General Univ, Alicante, Spain
    • ,
  • Montserrat Andreu

      Affiliations

    • Gastroenterology Department, Hospital del Mar, Barcelona, Catalonia, Spain
    • ,
  • Sapna Syngal

      Affiliations

    • Division of Population Sciences, Dana-Farber Cancer Institute and Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • C. Richard Boland

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Baylor University, Medical Center, Dallas, Texas
    • ,
  • Xavier Llor

      Affiliations

    • Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, Illinois
    • Corresponding Author InformationReprint requests Address requests for reprints to: Xavier Llor, MD, PhD, Department of Medicine and Cancer Center, University of Illinois at Chicago, 840 South Wood Street (M/C 716), Chicago, Illinois 60612. fax: (312) 996-5103

Received 12 October 2009 ,Accepted 8 January 2010.

References 

  1. Xicola RM, Llor X. Hereditary colorectal cancer. In:  Kim K editors. Colorectal cancer: early detection and prevention. Thorofare, NJ: Slack Inc; 2009;p. 149–166
  2. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–425
  3. Vasen HFA, Watson P, Mecklin J-P, et al. HNPCC I: new clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999;116:1453–1456
  4. Beck NE, Tomlinson IP, Homfray T, et al. Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg. 1997;84:233–237
  5. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138:560–570
  6. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer. Cancer Res. 1999;59:5068–5074
  7. Nakagawa H, Lockman JC, Frankel WL, et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 2004;64:4721–4727
  8. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–816
  9. Fishel R. Signaling mismatch repair in cancer. Nat Med. 1999;5:1239–1241
  10. Llor X, Pons E, Xicola RM, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res. 2005;11:7304–7310
  11. Mueller-Koch Y, Vogelsang H, Kopp R, et al. HNPCC—clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut. 2005;14:14
  12. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–1985
  13. Llor X, Pons E, Xicola RM, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res. 2005;11:7304–7310
  14. Abdel-Rahman WM, Ollikainen M, Kariola R, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene. 2005;17:17
  15. Sanchez-de-Abajo A, de la Hoya M, van Puijenbroek M, et al. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res. 2007;13:5729–5735
  16. Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127–138
  17. Nagasaka T, Koi M, Kloor M, et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology. 2008;134:1950–1960e1
  18. Gylling A, Ridanpaa M, Vierimaa O, et al. Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer. 2009;124:2333–2340
  19. Feinberg AP, Vogelstein B. Alterations in DNA methylation in human colon neoplasia. Semin Surg Oncol. 1987;3:149–151
  20. Goelz SE, Vogelstein B, Hamilton SR, et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187–190
  21. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–4642
  22. Xicola RM, Llor X, Pons E, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst. 2007;99:244–252
  23. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003;9:3362–3368
  24. Maruta H, Holden J, Sizeland A, et al. The residues of Ras and Rap proteins that determine their GAP specificities. J Biol Chem. 1991;266:11661–11668
  25. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–793
  26. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32:e38
  27. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66:5495–5503
  28. Matsuzaki K, Deng G, Tanaka H, et al. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res. 2005;11:8564–8569
  29. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  30. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–8686
  31. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55:1000–1006
  32. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–993
  33. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000;97:710–715
  34. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9:305–314
  35. Nagasaka T, Koi M, Kloor M, et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology. 2008;134:1950–1960
  36. Joensuu EI, Abdel-Rahman WM, Ollikainen M, et al. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res. 2008;68:4597–4605
  37. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 2007;13:3221–3228
  38. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2008;122:2767–2773
  39. Suzuki K, Suzuki I, Leodolter A, et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell. 2006;9:199–207
  40. Rodriguez J, Frigola J, Vendrell E, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006;66:8462–9468
  41. Pogribny IP, Beland FA. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci. 2009;66:2249–2261
  42. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene. 2005;24:7213–7223
  43. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–1738
  44. Guerrero S, Casanova I, Farre L, et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750–6756

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported by the Sirazi Foundation, Raymond Cole Memorial Foundation, and an internal grant from the Department of Medicine and the Cancer Center of the University of Illinois at Chicago (X.L.); National Institutes of Health grants CA72851 and funds from the Baylor Research Institute (C.R.B. and A.G.); and a grant from the Spanish Ministerio de Ciencia e Innovación (SAF 07-64873 to A.C.).

PII: S0016-5085(10)00102-2

doi: 10.1053/j.gastro.2010.01.035

Gastroenterology
Volume 138, Issue 5 , Pages 1854-1862.e1 , May 2010

Article Tools

* Image Usage & Resolution